Raymond James Financial
CVKD icon

Raymond James Financial’s Cadrenal Therapeutics CVKD Stock Holding History

Raymond James Financial’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,917
Closed -$23.1K – 5371
2025
Q2 		$23.1K Buy
+1,917
New +$28.5K ﹤0.01% 5542

Other funds holding CVKD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Raymond James Financial's CVKD Position: Q3 2025 in Review

Raymond James Financial sold out of Cadrenal Therapeutics (CVKD) in Q3 2025, closing a stake of 1,917 shares — an estimated $23.1K sold.

Raymond James Financial first reported a position in CVKD in Q2 2025 and held it in 1 quarter. The position peaked at $23.1K in Q2 2025. 20 funds tracked by Wall St. Rank hold CVKD as of Q3 2025.

  • Raymond James Financial reported no remaining Cadrenal Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 1,917 Cadrenal Therapeutics shares in Q3 2025, an estimated $23.1K.
  • Raymond James Financial first reported a position in Cadrenal Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Cadrenal Therapeutics position peaked at $23.1K in Q2 2025.
  • 20 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.